Regeneron Pharmaceuticals, Inc.: how funds voted at the meeting of 13 Jun 2025
- Ticker
- REGN
- Meeting
- Season
- year to 30 June 2025
- Filers reporting
- 1,295
- Ballot items
- 5
1,295 filers on Form N-PX reported votes at the Regeneron Pharmaceuticals, Inc. meeting of 13 Jun 2025. The records fall into 5 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.
This meeting is in the year to 30 June 2025. The latest season on file is the year to 30 June 2026. The page of Regeneron Pharmaceuticals, Inc. has the latest meeting.
If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.
The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .
The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.
The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.
The page gives records. It gives no investment advice and no advice on how to vote.
Season on this page: year to 30 June 2025. Filings read through . How the figures are made
The ballot
Item 1: Director elections
4 nominees. 75.2% of the reported votes are for. 198 filers withheld from or voted against at least one nominee.
3,943 vote records from 351 filers. 14 of the 348 filers that marked the item voted against management. 3 filers gave no management mark.
- Positions of 54 fund families
- For 37
- Against 4
- Split or no vote 13
- Against management 4
Item 2: Advisory vote on executive pay (say-on-pay)
2,251 vote records from 1,279 filers. 108 of the 1,243 filers that marked the item voted against management. 36 filers gave no management mark.
- Positions of 57 fund families
- For 56
- Against 1
- Against management 1
Item 3: Audit-related items (auditor ratification)
987 vote records from 351 filers. 8 of the 348 filers that marked the item voted against management. 3 filers gave no management mark.
- Positions of 54 fund families
- For 53
- Against 1
- Against management 1
Item 4: SHAREHOLDER RIGHTS AND DEFENSES: management items
The company's items in this category are shown together, because filers word and number them differently.
1,337 vote records from 337 filers. 0 of the 335 filers that marked the item voted against management. 2 filers gave no management mark.
- Positions of 53 fund families
- For 53
Item 5: CORPORATE GOVERNANCE: management items
The company's items in this category are shown together, because filers word and number them differently.
1,600 vote records from 301 filers. 3 of the 299 filers that marked the item voted against management. 2 filers gave no management mark.
- Positions of 45 fund families
- For 45
Positions of the fund families
A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.
KeyForAgainstAbstain or withholdSplit or no voteAgainst management
Questions
- How many filers reported votes at the Regeneron Pharmaceuticals, Inc. meeting?
- 1,295 Form N-PX filers reported votes at the meeting of 13 Jun 2025. On say-on-pay, 108 of 1,243 filers that marked the item voted against management (8.7%).
- Is this the result of the meeting?
- No. The page counts the filers that report on Form N-PX, and the shares they reported. Regeneron Pharmaceuticals, Inc. reports the result of a vote on Form 8-K.
- Why does the page show counts only for director elections?
- A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Regeneron Pharmaceuticals, Inc. with a meeting date within three days of 13 Jun 2025. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .